Metformin modifies glutamine metabolism in an in vitro and in vivo model of hepatic encephalopathy
Por:
Gil-Gómez A., Gómez-Sotelo A.I., Ranchal I., Rojas Á., García-Valdecasas M., Muñoz-Hernández R., Gallego-Durán R., Ampuero J., Romero-Gómez M.
Publicada:
1 ene 2018
Resumen:
Aim: to analyze the effect of metformin on ammonia production derived from glutamine metabolism in vitro and in vivo. Methods: twenty male Wistar rats were studied for 28 days after a porto-caval anastomosis (n = 16) or a sham operation (n = 4). Porto-caval shunted animals were randomized into two groups (n = 8) and either received 30 mg/kg/day of metformin for two weeks or were control animals. Plasma ammonia concentration, Gls gene expression and K-type glutaminase activity were measured in the small intestine, muscle and kidney. Furthermore, Caco2 were grown in different culture media containing glucose/glutamine as the main carbon source and exposed to different concentrations of the drug. The expression of genes implicated in glutamine metabolism were analyzed. Results: metformin was associated with a significant inhibition of glutaminase activity levels in the small intestine of porto-caval shunted rats (0.277 ± 0.07 IU/mg vs 0.142 ± 0.04 IU/mg) and a significant decrease in plasma ammonia (204.3 ± 24.4 µg/dl vs 129.6 ± 16.1 µg/dl). Glucose withdrawal induced the expression of the glutamine transporter SLC1A5 (2.54 ± 0.33 fold change; p < 0.05). Metformin use reduced MYC levels in Caco2 and consequently, SLC1A5 and GLS expression, with a greater effect in cells dependent on glutaminolytic metabolism. Conclusion: metformin regulates ammonia homeostasis by modulating glutamine metabolism in the enterocyte, exerting an indirect control of both the uptake and degradation of glutamine. This entails a reduction in the production of metabolites and energy through this pathway and indirectly causes a decrease in ammonia production that could be related to a decreased risk of HE development. © 2018. SEPD y and ARÁN EDICIONES, S.L.
Filiaciones:
Gil-Gómez A.:
Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC, Universidad de Sevilla, CiberEHD, Sevilla, Spain
Gómez-Sotelo A.I.:
Unit for Clinical Management of Digestive Diseases, Hospital Universitario de Valme, Sevilla, Spain
Ranchal I.:
Unit for Clinical Management of Digestive Diseases, Hospital Universitario de Valme, Sevilla, Spain
Rojas Á.:
Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC, Universidad de Sevilla, CiberEHD, Sevilla, Spain
García-Valdecasas M.:
Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC, Universidad de Sevilla, CiberEHD, Sevilla, Spain
Muñoz-Hernández R.:
Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC, Universidad de Sevilla, CiberEHD, Sevilla, Spain
Gallego-Durán R.:
Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC, Universidad de Sevilla, CiberEHD, Sevilla, Spain
Ampuero J.:
Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC, Universidad de Sevilla, CiberEHD, Sevilla, Spain
Unit for the Clinical Management of Digestive Diseases, Hospital Universitario Virgen del Rocío, Sevilla, Spain
Romero-Gómez M.:
Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC, Universidad de Sevilla, CiberEHD, Sevilla, Spain
Unit for the Clinical Management of Digestive Diseases, Hospital Universitario Virgen del Rocío, Sevilla, Spain
|